Understanding the Antiplasmodial Action of Resistance-Refractory Xanthoquinodin A1

ACS Infect Dis. 2024 Jun 14;10(6):2276-2287. doi: 10.1021/acsinfecdis.4c00232. Epub 2024 May 29.

Abstract

Our previous work identified a series of 12 xanthoquinodin analogues and 2 emodin-dianthrones with broad-spectrum activities against Trichomonas vaginalis, Mycoplasma genitalium, Cryptosporidium parvum, and Plasmodium falciparum. Analyses conducted in this study revealed that the most active analogue, xanthoquinodin A1, also inhibits Toxoplasma gondii tachyzoites and the liver stage of Plasmodium berghei, with no cross-resistance to the known antimalarial targets PfACS, PfCARL, PfPI4K, or DHODH. In Plasmodium, inhibition occurs prior to multinucleation and induces parasite death following 12 h of compound exposure. This moderately fast activity has impeded resistance line generation, with xanthoquinodin A1 demonstrating an irresistible phenotype in both T. gondii and P. falciparum.

Keywords: Xanthoquinodin, Fungal derived, Plasmodium, malaria, antiplasmodial.

MeSH terms

  • Animals
  • Anthraquinones / chemistry
  • Anthraquinones / pharmacology
  • Antimalarials* / chemistry
  • Antimalarials* / pharmacology
  • Drug Resistance*
  • Humans
  • Plasmodium berghei* / drug effects
  • Plasmodium falciparum* / drug effects
  • Toxoplasma* / drug effects

Substances

  • Antimalarials
  • Anthraquinones